Comparison Between TPRK Versus AAPRK in Correction of Myopia

June 22, 2018 updated by: Hossam Mohamed Moharram, Minia University

Comparison Between TPRK Versus AAPRK in Correction of Myopia and Myopic Astigmatism

PURPOSE: The aim of the study is to compare visual acuity means, refractive results, safety, and efficacy of TPRK with AAPRK as primary outcomes and surgical time, pain scores, haze levels, and healing time as secondary outcomes.

SETTING: Security Forces Hospital, Ophthalmology Department, Riyadh, Kingdom of Saudi Arabia.

DESIGN: Prospective, consecutive, nonrandomized case-control comparative study.

. METHODS: A total of 200 eyes of 100 patients were included. One hundred eyes underwent TPRK in the right eye (study group) and 100 eyes underwent AAPRK in the left eye (control group). Ablations performed with the Schwind Amaris, 750S. Clinical outcomes were compared Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.

Study Overview

Detailed Description

Introduction Previous studies document that, although Laser in situ keratomileusis (LASIK) is the most worldwide performed refractive procedure, surface ablation may be safer to avoid flap complications, corneal weakening, and a higher risk of iatrogenic keratectasia associated with LASIK and thus the era of surface ablation emerged as an alternative (1). Photorefractive keratectomy (PRK) is one of the surface ablation procedures and performed after corneal epithelial debridement accompanied by post-operative pain, discomfort, and high grade of corneal haze, all of which limit its popularity (2). The traditional method for corneal epithelium removal before excimer LASER was manual scraping, which was later enhanced by using an alcohol solution 20% or brush (3). In 2003, Camellin introduced a new alcohol-assisted technique called laser-assisted subepithelial keratectomy (LASEK) that allowed the epithelium to be preserved as a flap and applied back to the stromal corneal bed after laser treatment (4). Also in 2003, Pallikaris invented epithelial laser in situ keratomileusis (Epi-LASIK) which is another method that uses the epithelial flap and performed with a microkeratome (called epi-keratome) with a blunt oscillating blade. After trans-epithelial photorefractive keratectomy (TPRK) was introduced, where removal of the epithelium is done by phototherapeutic ablation followed by refractive ablation of the corneal stroma. Several studies emerged and advocated many techniques for epithelial removal , but this 2-step technique was not worldwide used due to the prolonged surgery time with the older generation of lasers, corneal dehydration, increased post-operative pain, and a deficiency of adjusted nomograms (5). When new generations of faster lasers, improved ablation algorithms, and nomograms have emerged, it allowed development of a new TPRK non touch: all-surface ablation technique which allows ablation the corneal epithelium and stroma in a single-step with one ablation profile. This aspheric profile is calculated according to data from the literature estimating that the normal corneal epithelial thickness is 55 μm centrally and 65 peripherally at 4 mm radially from the center (6). A number of recent studies demonstrated that this single-step TPRK is a relatively new procedure with many advantages such as, reduced surgical time, minimizing the size of epithelial defect to that required for stromal ablation, no alcohol use avoiding potential toxicity to the limbal cells, less post-operative pain and corneal haze with rapid healing time and faster visual recovery (7).Thus, there is a need for an updated comparative evaluation based on a larger number of eyes. The aim of our study is to compare 6-months un-corrected distant visual acuity (UDVA) and best corrected distant visual acuity (BCDVA) means, refractive results, safety, and efficacy of single-step TPRK with alcohol-assisted PRK (AAPRK) as primary outcomes and comparison of surgical time, pain scores, and haze levels, complete epithelial healing time, as secondary outcomes among the two procedures when used to correct mild to moderate myopia and myopic astigmatism.

Subjects and methods This study is a prospective, consecutive, nonrandomized case-control study that includes eyes that underwent either single-step TPRK or AAPRK between February 2017 and April 2018, at the Security Forces Hospital, Ophthalmology department, Riyadh, Kingdom of Saudi Arabia. The study was approved by the local ethical board committee. Before the surgical procedure, each patient was adequately informed about the study as well as the risks and benefits of the surgery, and signed informed consent in accordance with the Declaration of Helsinki.

A total of 200 eyes of 100 consecutive patients were included; One hundred eyes underwent TPRK (study group) and 100 eyes underwent AAPRK (control group). The study design choice of the procedure was fixed for each patient: the right eye underwent TPRK and the contra-lateral left eye AAPRK. Patients demographics and preoperative variables are demonstrated in Table (1). There are no significant differences in pre-operative variables of patients in the TPRK and AAPRK groups except the patients' genders. The percentage of females is 77% and males 23%. Patients who attended all visits, without any missing data, were included in the statistical analysis.

Preoperative Examination The preoperative examination included UDVA, BCDVA, manifest and cycloplegic refraction, slit lamp biomicroscopy, tonometry, Pentacam camera (OCULUS- Netzteil Art., pentacam HR, Germany), tomography (Sirius, SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany), and dilated fundus examination using binocular ophthalmoscopy. Contact lenses use and medical history, including any systemic diseases, were recorded.

Surgical Technique All surgeries were performed with 6th-generation Amaris excimer LASER 193, version 750 S (Schwind eye-tech-solutions GmbH& Co.KG, Mainparkstrasse, Kleinostheim, Germany). Ablations were based on aberration-free algorithms calculated using ORK-CAM software with beam size 0.54 mm full width and high-speed eye tracking. Treatments were performed by 2 surgeons (BA & ESH ) using an identical surgical protocol. The treatments were mostly aimed at emmetropia. Before the surgery, tetracaine hydrochloride 0.5% ophthalmic solution (Bausch & Lomb, Minims) and moxifloxacin 0.5% (Vigamox, Alcon Co.) drops were instilled 3 times within a 5-minutes interval. The eyelids were prepared with antiseptic Chlorohexidine Gluconate 0.05% solution (Saudi Medical Solution Company) and opened using a wire lid speculum. In the AAPRK group, the cornea was exposed to a 20% ethyl alcohol solution for 25 seconds with the use of a well. Subsequently, a superficial cut of the epithelium was made with either an 8.5 or 9.5 mm diameter trephine. The epithelium was mechanically debrided with the well or with a blunt spatula, then LASER treatment with the same machine was initiated. In the TPRK group, where aspheric aberration-free TPRK ablation algorithm was used (Schwind eye-tech-solutions), the epithelium was removed during laser ablation only from the area of the total ablation zone. In both groups and in all cases, immediately after treatment, the eye was washed with a balanced salt solution (BSS) for 20 seconds. Then, to fight against post-operative corneal haze, mitomycin C 0.02% (MMC) was applied for 30 seconds followed by copious irrigation of the eye with BSS. Intra-operative complications were not noted and surgical time starting from eye lid speculum insertion to the time of its removal at the end of the procedure were recorded. After the surgery, a bandage contact lens was applied (BIOMEDICS Evolution CL ocufilcon D 45%, water 55%) for 7 days. The postoperative regimen included tobradex eye drops 0.3% (Tobramycin 0.3% - dexamethazone 0.1% sterile eye drops, Alcon Co.) with tapering dose for 1 month starting with QID/ 1 week, TID/ 1 week, BID/ 1 week and once a day/1 week, moxifloxacin drops 0.5% (Vigamox, Alcon Co.) for 2 weeks, and sodium hyaluronate 0.2% (Hyfresh eye drops, Jamjoom Pharma Co.) drop / 2 hours and a gradual decreasing of the frequency for 3 months. Pain killer oral medication tablet/ 6 hours was used in the first post-operative days if needed.

Postoperative Examinations Patients were instructed to visit the clinic for postoperative examinations and follow up after 1 day, 1 week, 1 month, 3 months and 6 months. Examinations at 1 day, 1 week, 1 month, 3 months, and 6 months included UDVA ,but the BCDVA and manifest refraction were measured at 1, 3, and 6 months. Slit lamp biomicroscopy was done in each visit. Corneal haze grading was evaluated according to Fantes et al., 1990 proposal (0 = no haze; 0.5 = trace haze on oblique illumination; 1 = corneal cloudiness not interfering with the visibility of fine iris details; 2 = mild effacement of fine iris details; 3 and 4 = details of the lens and iris not discernible). Healing time in which complete re-epithelialisation occurred in both eyes were recorded. In post-operative day 1, day 3 and week 1, We used a discrete, 11-category numeric pain scale (NPS, 0 = no pain and 10 = the worst possible pain) to evaluate pain score in each eye and patients response were recorded at early postoperative period. Six months post-operatively, patients were asked about the overall satisfaction with each procedure as high, moderate, low, and not satisfied, and whether they would decide to have the surgery again (yes, no) were recorded.

Statistical Analysis Patients' data were entered in Microsoft Excel, copied and analyzed using Sigma Plot-Scientific Data Program for the 2 groups, Paired student's t-test was used for the UDVA & BCDVA means in decimal values and for MRSE means. Mann-Whitney test was used for pain scores, haze levels, and healing time. For all tests, a (P value < 0.05) was considered statistically significant. A Graph Pad Prism 5 program was used for graphs constructions.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Al Minya, Egypt
        • Shaaban A Elwan
    • Central
      • Riyadh, Central, Saudi Arabia, 11481-3643
        • Security Forces Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 54 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age over 18 years
  • Primary myopia or compound myopic astigmatism
  • Preoperative manifest refraction spherical equivalent (MRSE) within the range of -1.50 to -7 D
  • Stable refraction for at least 1 year before the surgery
  • Contact lens discontinuation for at least 3 weeks
  • Estimated stromal corneal bed thickness of >330 μm at the thinnest location.

Exclusion Criteria:

  • Previous ocular surgery
  • Active ocular diseases
  • Corneal dystrophy
  • Retinal disease
  • Glaucoma
  • Dry eye
  • History of severe eye trauma
  • Irregular astigmatism or suspected keratoconus on corneal topography
  • Systemic disease that could affect corneal wound healing such as collagen diseases, diabetes mellitus, and pregnancy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NON_RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Transepithelial PRK
Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Other Names:
  • TPRK
ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Other Names:
  • APRK
ACTIVE_COMPARATOR: Alcohol assisted PRK
Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Other Names:
  • TPRK
ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
Other Names:
  • APRK

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Visual acuity means
Time Frame: 6 months
visual acuity means in decimal value from minimum 0.1 to maximum 1.2.
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Surgical time
Time Frame: 6 months
surgical time in seconds
6 months
Pain scores
Time Frame: 6 months
pain scores,from 0 -10, 11-category numeric pain scale (NPS, 0 = no pain and 10 = the worst possible pain)
6 months
Haze levels
Time Frame: 6 months
haze levels from 0 o 4 (0 = no haze; 0.5 = trace haze on oblique illumination; 1 = corneal
6 months
Complete epithelial healing time
Time Frame: 6 months
complete epithelial healing time in days.
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 15, 2017

Primary Completion (ACTUAL)

April 15, 2018

Study Completion (ACTUAL)

April 25, 2018

Study Registration Dates

First Submitted

April 27, 2018

First Submitted That Met QC Criteria

June 22, 2018

First Posted (ACTUAL)

June 26, 2018

Study Record Updates

Last Update Posted (ACTUAL)

June 26, 2018

Last Update Submitted That Met QC Criteria

June 22, 2018

Last Verified

June 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MiniaU2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myopia

Clinical Trials on Transepithelial photorefractive keratectomy

3
Subscribe